AVXL

Anavex Life Sciences Corp.

3.77 USD
+0.07 (+1.89%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Anavex Life Sciences Corp. stock is down -12.53% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Jun 13:42 18 Oct, 2024 5.00 PUT 189 67

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.